Categories Analysis, Health Care, Trending Stocks

Hopes high for Mylan’s Upjohn merger even as epidemic mars short-term prospects

A new company called Viatris will be formed by combining Mylan with Upjohn

Drugmaker Mylan (NASDAQ: MYL) is all set for a transformation with its planned merger with Upjohn, the generic medicine business of Pfizer (PFE). The transaction, which is expected to close mid-2020, is of great significance for the company at a time when it is facing multiple challenges, including sales slump in North America and pricing issues.

Of late, Mylan has been pinning hope on its biosimilar business, with several candidates at different stages of development and neutropenia drug Fulphila recently securing FDA approval. The company has been gaining market share aided by the positive response to its biosimilar to Roche Holding’s cancer drug Herceptin. Ogivri was rolled out last year after a legal battle.

The Pros

These positive factors, combined with the Pfizer tie-up, should help the company regain strength this year. Incoming chief financial officer Sanjeev Narula, who is expected to assume office at the combined entity later this year, will have several key tasks to perform.

Stock Movement

Mylan’s stock was on the recovery path early this year, after last year’s dismal performance, but it pulled back last month amid the coronavirus-linked selloff. Market watchers predict a strong rebound in the latter part of the year and the majority of them recommend buying the stock.

Mylan (MYL) Q3 earnings surpass estimates; revenues miss

Currently, the main challenge facing the company is lingering concerns over last year’s lawsuit in which several generic drugmakers including Mylan were charged with price-fixing. The final outcome of the case could play a key role in deciding the company’s future, given the unfavorable market conditions including the falling prices of generic drugs in the US.

Q4 Profit up

Reflecting the strong demand across key markets, Mylan’s revenues grew 4% to $3.2 billion in the fourth quarter. Consequently, earnings, adjusted for one-off items, moved up 8% to $1.40 per share during the three-month period. While the bottom-line topped the Street view, revenues fell short of expectations.

Mylan’s stock, which has been in a free fall for more than a year, extended the losses in recent weeks as the COPID-19 crisis battered the markets. At $15.04, the shares closed the last trading session down 48% from last year. The stock contracted about 20% this year alone.

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top